BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11401675)

  • 21. Plasminogen activation in human acute leukaemias.
    Scherrer A; Wohlwend A; Kruithof EK; Vassalli JD; Sappino AP
    Br J Haematol; 1999 Jun; 105(4):920-7. PubMed ID: 10554801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
    Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
    Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
    Lyon PB; See WA; Xu Y; Cohen MB
    Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
    Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
    World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
    Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
    Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes.
    Zhang T; Zhou HM; Liu YX
    Mol Hum Reprod; 1997 Mar; 3(3):223-31. PubMed ID: 9237248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
    Muehlenweg B; Sperl S; Magdolen V; Schmitt M; Harbeck N
    Expert Opin Biol Ther; 2001 Jul; 1(4):683-91. PubMed ID: 11727504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
    Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.